GSK 223584_MiDAS

Hematological neoplasms
Myelodysplastic Syndrome (MDS)
Follow-Up Treatment
This is an open-label, Phase 2 study, evaluating the safety, efficacy and PK of Momelotinib, in participants with anemia that requires RBC transfusions due to LR-MDS, defined as very low risk to intermediate risk disease.
This is an open-label, Phase 2 study, evaluating the safety, efficacy and PK of Momelotinib, in participants with anemia that requires RBC transfusions due to LR-MDS, defined as very low risk to intermediate risk disease.